SARS-CoV-2 Screening Test for Japanese Returnees From Wuhan, China, January 2020

  • Satoshi Kutsuna
    Disease Control and Prevention Center, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan
  • Tadaki Suzuki
    COVID-19 NIID Evacuation Flight Laboratory Testing Team (NEFLATT), National Institute of Infectious Diseases, Shinjuku-ku, Tokyo, Japan
  • Kayoko Hayakawa
    Disease Control and Prevention Center, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan
  • Shinya Tsuzuki
    AMR Clinical Reference Center, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan
  • Yusuke Asai
    AMR Clinical Reference Center, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan
  • Tetsuya Suzuki
    Disease Control and Prevention Center, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan
  • Satoshi Ide
    Disease Control and Prevention Center, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan
  • Keiji Nakamura
    Disease Control and Prevention Center, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan
  • Yuki Moriyama
    Disease Control and Prevention Center, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan
  • Noriko Kinoshita
    Disease Control and Prevention Center, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan
  • Naoto Hosokawa
    Department of Infectious Disease, Kameda Medical Center, Kamogawa City, Chiba, Japan
  • Ryosuke Osawa
    Department of Infectious Disease, Kameda Medical Center, Kamogawa City, Chiba, Japan
  • Ryosuke Yamamuro
    Department of Infectious Disease, Kameda Medical Center, Kamogawa City, Chiba, Japan
  • Yutaro Akiyama
    Disease Control and Prevention Center, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan
  • Yusuke Miyazato
    Disease Control and Prevention Center, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan
  • Hidetoshi Nomoto
    Disease Control and Prevention Center, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan
  • Takato Nakamoto
    Disease Control and Prevention Center, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan
  • Masayuki Ota
    Disease Control and Prevention Center, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan
  • Sho Saito
    Disease Control and Prevention Center, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan
  • Masahiro Ishikane
    Disease Control and Prevention Center, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan
  • Shinichiro Morioka
    Disease Control and Prevention Center, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan
  • Kei Yamamoto
    Disease Control and Prevention Center, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan
  • Mugen Ujiie
    Disease Control and Prevention Center, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan
  • Mari Terada
    Disease Control and Prevention Center, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan
  • Fukumi Nakamura-Uchiyama
    Department of Infectious Diseases, Ebara Hospital, Tokyo Metropolitan Health and Hospitals Corporation, Ota-ku, Tokyo, Japan
  • Toshinori Sahara
    Department of Infectious Diseases, Ebara Hospital, Tokyo Metropolitan Health and Hospitals Corporation, Ota-ku, Tokyo, Japan
  • Masahiro Sano
    Department of Infectious Diseases, Toshima Hospital, Tokyo Metropolitan Health and Hospitals Corporation, Itabashi-ku, Tokyo, Japan
  • Akifumi Imamura
    Department of Infectious Diseases, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku, Tokyo, Japan
  • Noritaka Sekiya
    Department of Infection Prevention and Control, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku, Tokyo, Japan
  • Kazuaki Fukushima
    Department of Infectious Diseases, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyo-ku, Tokyo, Japan
  • Akihiko Kawana
    Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, Tokorozawa City, Saitama, Japan
  • Yuji Fujikura
    Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, Tokorozawa City, Saitama, Japan
  • Tomoya Sano
    Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, Tokorozawa City, Saitama, Japan
  • Ryohei Suematsu
    Division of Infectious Diseases and Respiratory Medicine, Department of Internal Medicine, National Defense Medical College, Tokorozawa City, Saitama, Japan
  • Naoya Sakamoto
    Department of Infectious Diseases, Tokyo Metropolitan Bokutoh General Hospital, Sumida-ku, Tokyo, Japan
  • Kaoru Nagata
    Japanese Red Cross Musashino Hospital, Musashino City, Tokyo, Japan
  • Tomoyuki Kato
    Japanese Red Cross Musashino Hospital, Musashino City, Tokyo, Japan
  • Harutaka Katano
    COVID-19 NIID Evacuation Flight Laboratory Testing Team (NEFLATT), National Institute of Infectious Diseases, Shinjuku-ku, Tokyo, Japan
  • Takaji Wakita
    COVID-19 NIID Evacuation Flight Laboratory Testing Team (NEFLATT), National Institute of Infectious Diseases, Shinjuku-ku, Tokyo, Japan
  • Haruhito Sugiyama
    National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan
  • Norihiro Kokudo
    National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan
  • Norio Ohmagari
    Disease Control and Prevention Center, National Center for Global Health and Medicine, Shinjuku-ku, Tokyo, Japan

説明

<jats:title>Abstract</jats:title> <jats:sec> <jats:title>Background</jats:title> <jats:p>Severe acute respiratory syndrome–related coronavirus 2 (SARS-CoV-2) was found to be the causative microorganism of coronavirus disease 2019 (COVID-19), which started to spread in Wuhan, China. This study was to evaluate the effectiveness of questionnaire, symptoms-based screening, and polymerase chain reaction (PCR) screening of returnees from COVID-19-endemic areas on a chartered flight, to examine the proportion of infected persons and the proportion of asymptomatic persons among infected persons who returned from Wuhan.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>A retrospective cohort study was done in 7 tertiary medical institutions in Japan. A total of 566 Japanese who returned from Wuhan participated in the study.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>Overall, 11 of the 566 passengers had a positive SARS-CoV-2 PCR result for pharyngeal swabs and 6 were asymptomatic. Only fever differed between SARS-CoV-2-positive and -negative individuals (P &lt; .043). Six of the 11 PCR-positive individuals were asymptomatic; 4 remained positive on day 10, and 1 asymptomatic person tested positive up to day 27. Two of the 11 were negative on the first PCR test and positive on the second.</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions</jats:title> <jats:p>Our results will be important insights on screening returnees from locked-down cities, as well as providing important data on the proportion of asymptomatic individuals infected with SARS-CoV-2. A 13-day observation period and a second round of PCR may be effective to screen patients, including asymptomatic infections.</jats:p> </jats:sec>

収録刊行物

被引用文献 (4)*注記

もっと見る

問題の指摘

ページトップへ